

EURETINA 2025 Preview – Table of Contents

General Overview and Conference Themes	<u>3-5</u>
 Noteworthy Scientific presentations at EURETINA'25 	6-67
Key Topics From Notable Presentations	7-10
Focus of Key Industry Sponsored Sessions at EURETINA'25	11-15
Notable Presentations at EURETINA'25	16-62
Key Sponsored Sessions Information	63-67
Noteworthy AI / ML Presentations	68-81
Key AI / ML Themes	69-71
Key AI/ML Presentations Information	72-81
• Get in touch with LucidQuest	82





EURETINA 2025 - General Overview



 Global participation: Ophthalmologists, researchers, and industry leaders are expected to convene, advancing retinal disease science and care worldwide



 Multidisciplinary agenda: Sessions will span AMD, DME, inherited retinal diseases, AI imaging, surgical retina, and health equity



 Innovation spotlight: Emerging therapies in complement inhibition, gene therapy, and sustained drug delivery platforms are anticipated to reshape treatment landscapes



 Patient-centered outcomes: Real-world evidence, quality of life, and treatment burden analyses are projected to drive more holistic patient management



 Digital and personalized care: AI-powered diagnostics, teleophthalmology, and biomarker-driven strategies are expected to support precision and accessible eye care



 Collaborative networks: International registries and multi-country trials are anticipated to expand, strengthening evidence generation and harmonizing global standards of retinal care





EURETINA 2025 - Conference Themes (1/2)

- Redefining Treatment Goals in AMD: Focus is shifting from short-term visual gains toward durability, functional outcomes, and reducing treatment burden
- Patient-centered Perspectives: Patient voices, adherence data, and lived experiences are anticipated to guide future trial endpoints and practice standards



- Real-World Implementation: Integration of novel biologics, implants, and AI imaging into real-world practice is projected to shape cost-effectiveness and adoption
- AI Imaging and Biomarkers: OCTA, widefield imaging, and AIdriven biomarkers are expected to refine the prediction of disease activity and progression
- Gene and Cell Therapies: Expanding programs in Stargardt, XLRP, and RP are projected to redefine hereditary retinal disease care





EURETINA 2025 - Conference Themes (2/2)

- Drug Delivery & Devices: Port delivery systems, suprachoroidal injections, and new biosimilars are anticipated to broaden treatment access
- Surgical Retina Innovation: Advances in vitrectomy efficiency, tamponade strategies, and robotics are set to modernize surgical care



- Global Epidemiology & Equity: Studies on socioeconomic disparities, geographic atrophy progression, and treatment access are expected to highlight unmet needs
- Rare Diseases & Oncology: Uveal melanoma genomics, vitreoretinal lymphoma, and inflammatory chorioretinopathies are projected to expand research focus





Key Topics From Notable Presentations (1/4)



Geographic Atrophy, Intermediate & Non-Exudative AMD:

 Geographic atrophy sessions are set to integrate OAKS, DERBY, GALE, and GATHER1/2 progression insights with ARCHER II ANX007 design, eDREAM GAL-101 eyedrops, VERDANT C3 inhibition, VOY-101 complement gene therapy, OCU410 modifier therapy, plus MACUSTAR, INTERCEPT-AMD, AGAIN acceptability, and natural-history baselines data



AMD - Neovascular / PCV (nAMD):

 Therapy for nAMD is set to spotlight faricimab and aflibercept 8 mg across SPECTRUM, SALWEEN, FAR WEST, FARWIDE-nAMD, TRUCKEE, and AVONELLE-X, comparing durability, fluid control, extension intervals, and safety, alongside switching analyses and Taiwan head-to-head outcomes, including treatment-resistant subgroups and biomarkers



Diabetic Retinopathy & DME:

 DME programs are set to report PHOTON extension, YOSEMITE/RHINE biomarker analyses, ELEVATUM equity outcomes, FARWIDE-DME and TAHOE real-world effectiveness, VERONA EYP-1901 results, HELIOS OTX-TKI signals, AMARONE Restoret data, SPECTRUM aflibercept 8 mg experiences, and SPECTRA 4D-150 interim findings alongside ILUVIENbased insights registries





Key Topics From Notable Presentations (2/4)



Surgical Retina, Devices, Imaging, High Myopia, Biosimilars & QoL:

 Practice innovation is expected to cover BRAVE microscope training, 1,2-SIT injection methods, ChatGPT-40 recurrence detection, teleophthalmology screening, Zhang Ring validation, surgical efficiency studies, YAG floater trials, biosimilar experiences with Tyalia and Oceva, endophthalmitis analyses, high-myopia DIMS outcomes, and suprachoroidal advances



Inherited Retinal Diseases & Gene/Cell Therapies:

 Gene and cell therapy advances are expected to feature SKYLINE and DAWN XLRP programs, OCU400 modifier therapy, LUCE-1 AAVB-081, VP-001 PRPF31 therapy, PRODYGY RdCVF, MCO-010 REMAIN extension, and PERCEIVE voretigene outcomes, shaping endpoints, safety, durability, and paired-eye trial designs strategies



Uveitis, Inflammation & Ocular Tumors:

 Inflammation-oncology sessions are projected to present long-term adalimumab control, compare dexamethasone versus fluocinolone for uveitic edema, analyze dengue and e-cigarette uveitis risks, detail pediatric epidemiology, report Bartonella outcomes, characterize vitreoretinal lymphoma and choroidal infiltration radiotherapy, and quantify choroidal-nevus vascularity with OCT





Key Topics From Notable Presentations (3/4)



• Retinal Vascular Occlusions (RVO/CRVO/BRVO/CRAO):

 Retinal occlusion research is projected to highlight QUASAR primary endpoints for aflibercept 8 mg, HERMES perfusion changes, TenCRAOS thrombolysis outcomes, and BALATON/COMINO post-hoc analyses linking early leakage resolution to extended dosing intervals, informing individualized management across BRVO, CRVO, and retinal artery occlusion



AMD Epidemiology, Imaging & Biomarkers:

 Imaging-biomarker research is expected to emphasize Beijing Eye Study findings on RPD and hyperreflective bodies, ACTOR and COCTAEYL OCTA activity metrics, OCT Fx Delphi consensus, PINNACLE microperimetry correlations, eye-tracking biomarkers, Singapore octogenarian atrophy prevalence, and drusenoid evolution using morphology-structural software analyses





Key Topics From Notable Presentations (4/4)



Pachychoroid Spectrum & Central Serous Chorioretinopathy:

 Pachychoroid-CSCR content is poised to compare topical difluprednate versus eplerenone, present Beijing Eye Study prevalence data, evaluate brolucizumab in chronic CSCR without CNV, and refine pachychoroid neovasculopathy resolution using swept-source OCTA metrics, informing therapeutic choices and imaging-based response assessment spectrum



High Myopia & Degenerative Myopia:

 High-myopia research is set to track CNV-related maculopathy progression in multicenter cohorts, quantify microvascular alterations via OCT/OCTA, and assess changes with DIMS myopia-control lenses over 36 months, including pachymetry and anterior-segment metrics. A tractional myopic maculopathy progression study is planned



Focus of Key Industry-Sponsored Sessions at EURETINA 2025 (1/5)





- Focus Areas: Translating Science to Real-World Practice in Retinal Care
- Sessions will emphasize evolving clinical practice from lab to patient, interpreting real-world data for AMD/DME, and leadership in shaping the future of retinal care



Roche:

- Focus Areas: Beyond VEGF-A and Continuous Care Models
- Presentations will cover novel approaches in nAMD and DME, patient voices in continuous delivery, and strategies to expand treatment durability beyond VEGF inhibition



Ora:

- Focus Areas: Smarter Clinical Trial Design & Execution
- Discussions will highlight innovation in global trial design, operational efficiency, and strategies for smarter clinical execution in ophthalmology research



Focus of Key Industry-Sponsored Sessions at EURETINA 2025





- Focus Areas: Surgical Efficiency in Vitreoretinal Procedures
- Sessions will demonstrate advances in achieving superior efficiency, precision, and outcomes in vitreoretinal surgery through novel surgical platforms



- Focus Areas: Next-Generation Retinal Imaging
- Talks will focus on advancing imaging modalities, highlighting current trends and future directions for enhanced diagnosis and monitoring in retinal disease

Lumibird Medical:

- Focus Areas: Rethinking Laser-Based Retinal Treatments
- Presentations will explore innovations in laser therapy, reframing vitreous and retinal treatment paradigms for improved clinical outcomes



Focus of Key Industry-Sponsored Sessions at EURETINA 2025 (3/5)





- Focus Areas: Inflammation & AI-Driven Biomarkers in Retinal Vascular Disease
- Sessions will spotlight evolving management of DME and RVO with anti-inflammatory strategies and AI-driven OCT biomarker analysis for optimized treatment



- Focus Areas: Ultra-Widefield Imaging and OCT Innovation
- Presentations will showcase the role of advanced imaging—including ultra-widefield and navigated OCT—in enhancing patient care and clinical decision-making

Astellas:

- Focus Areas: Geographic Atrophy Patient Management
- Sessions will engage clinicians in case-based approaches to GA, emphasizing real-world patient management and clinical decisionmaking in advanced AMD



Focus of Key Industry-Sponsored Sessions at EURETINA 2025 (4/5)





- Amgen:
- Focus Areas: Biosimilars in Ophthalmology
- Discussions will decode biosimilar development, clinical integration, and the role of biosimilars in expanding access to retinal therapeutics



Espansione Group:

- Focus Areas: Light Modulation & Photobiomodulation (PBM)
- Sessions will explore LLLT/photobiomodulation as a new frontier for retinal care and beyond, highlighting novel light-based therapeutic approaches



Ocular:

- Focus Areas: Durability with OTX-TKI for Retinal Disease
- Presentations will explore OTX-TKI's potential to extend treatment intervals and improve durability for chronic retinal diseases



Focus of Key Industry-Sponsored Sessions at EURETINA 2025 (5/5)





Zeiss:

- Focus Areas: Imaging & Visualization in Diabetic Retinopathy
- Sessions will emphasize diagnostic imaging and advanced surgical visualization tools to improve outcomes in diabetic retinopathy



LumiThera:

- Focus Areas: Photo-biomodulation in Dry AMD
- Presentations will share long-term follow-up data from the LIGHTSITE trials, highlighting the durability and clinical benefit of PBM in dry AMD



4DMT:

- Focus Areas: Intravitreal Gene Therapy for Retinal Vascular Disease
- Talks will present advances with 4D-150, showcasing durable gene therapy approaches for nAMD and DME



Notable Presentations And Late-breaking Sessions At EURETINA 2025



Notable Presentations And Late-breaking Sessions AMD – Geographic Atrophy, Intermediate & Non-Exudative AMD (1/5)



Date	Author	Title
04 Sep 2025	Dr. Ana Margarida Ferreira	Non-Exudative Macular Neovascularization: A 3-year follow-up study assessing the progression for exudative or atrophic late AMD
04 Sep 2025	MARIAPIA LATERZA	Photobiomodulation-induced outer retinal and choriocapillaris remodeling in intermediate age-related macular degeneration: short-term results
04 Sep 2025	Dr. Nimet Zeynep Tıraş	Effects of Autologous Subtenon Platelet-Rich Plasma on Geographic Atrophy Progression, Visual Function, and Quality of Life in Advanced Dry AMD: A Prospective Study
04 Sep 2025	Dr. Fuad Makkouk	VERDANT Phase 2 Trial: Evaluating the Novel C3 Inhibitor BI-C vs Active Comparator in Geographic Atrophy Secondary to AMD
04 Sep 2025	Chang Ki Yoon	Geographic atrophy progression in Korea: multicenter study
04 Sep 2025	Marta Ugarte	A Comparative Analysis of Six-Month change in Best-Corrected and Low-Luminance Visual Acuities by Lesion Size in i-GAIN, a Non-Interventional Study on Geographic Atrophy



Notable Presentations And Late-breaking Sessions AMD – Geographic Atrophy, Intermediate & Non-Exudative AMD (2/5)



Date	Author	Title
04 Sep 2025	Mr Dimitrios Kazantzis	Baseline Structural and Functional Characteristics of a Prospective Natural History Study on Geographic Atrophy: Early Signs of Progression in Foveal-Sparing and Foveal-Involving Lesions
04 Sep 2025	Prof. Robyn Guymer	Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights from the Phase 3 OAKS and DERBY Trials
04 Sep 2025	Prof. Francesco Bandello	ReNEW, a Phase 3 Clinical Trial Evaluating Elamipretide in Dry Age-Related Macular Degeneration and Geographic Atrophy: Study Design and Patient Baseline Demographics
04 Sep 2025	Dr. Dilsher Dhoot	Early Versus Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48 Month Results from OAKS, DERBY, and GALE Open-Label Extension
04 Sep 2025	Dr. Gabriella De Salvo	Ellipsoid zone integrity features linked to differential shifts in geographic atrophy growth rate in the GATHER1 and GATHER2 clinical trials
05 Sep 2025	Dr. Omer Triviski	eDREAM: A Phase 2 Study with GAL-101 Eyedrops in Patients with Non-Foveal Geographic Atrophy (GA)



Notable Presentations And Late-breaking Sessions AMD – Geographic Atrophy, Intermediate & Non-Exudative AMD (3/5)



Date	Author	Title
05 Sep 2025	Miss Arevik Ghulakhszian	The AGAIN (Acceptability of Geographic AtrophyINjections) study:Is functional benefit critical to patient acceptability? A UK-based cross-sectional study
05 Sep 2025	Philip Rosenfeld	Clinical Trial Endpoints in Intermediate AMD
05 Sep 2025	Usha Chakravarthy	Functional Endpoints in Geographic Atrophy: Considerations for Clinical Trials
05 Sep 2025	Stela Vujosevic	Rationale and Study Design for ARCHER II, a Randomized Phase 3 Clinical Trial of ANX007 in Participants with dry AMD with GA
05 Sep 2025	Syed Shah	Novel Modifier Gene Therapy for Geographic Atrophy: Phase 1/2 Study Update for OCU410
05 Sep 2025	Baruch Kuppermann	AI analysis of OCT images from a Phase 1b study of Fas inhibition with ONL1204 as a treatment for geographic atrophy secondary to age-related macular degeneration.



Notable Presentations And Late-breaking Sessions AMD – Geographic Atrophy, Intermediate & Non-Exudative AMD (4/5)



Date	Author	Title
05 Sep 2025	Jordi Monés	Phase 2a SIGLEC Study: Changes in Hyper-autofluorescence Area and RPE/Outer Retinal Layer Thickness Following a Single Injection of AVD-104 for the Treatment of Geographic Atrophy
05 Sep 2025	Dr. Omer Triviski	First in Human Results of VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy
05 Sep 2025	Huma Qamar	ArMaDa Trial update: A One-Time Modifier Gene Therapy for Geographic Atrophy from the Phase 1/2 OCU410 study
06 Sep 2025	Prof. Dr. Robert Finger	MACUSTAR - A Multicenter, prospective, European clinical study: update
06 Sep 2025	Sobha Sivaprasad	INTERCEPT-AMD – An imaging study of Intermediate AMD
06 Sep 2025	Dr. Justis Ehlers	Optical Coherence Tomography to Function (OCT Fx) Delphi Study: Establishing a Global Consensus on Applications of Ellipsoid Zone Integrity for Age-related Macular Degeneration




Notable Presentations And Late-breaking Sessions AMD – Geographic Atrophy, Intermediate & Non-Exudative AMD (5/5)



Date	Author	Title
06 Sep 2025	Bjørn André Helland-Hansen	Eye-Tracking-Derived Foveal Biomarkers and Functional Alterations in Dry AMD: Findings from a Controlled Clinical Study
06 Sep 2025	Dr. med. Sophie Frank-Publig	Pointwise structure-function correlation between focal event-targeted microperimetry and the first sign of conversion to advanced AMD in the PINNACLE study
06 Sep 2025	Prof. Diana Do	LIGHTSITE IIIB: An Open-Label, Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of Photobiomodulation in Subjects with Dry Age-Related Macular Degeneration
07 Sep 2025	Usha Chakravarthy	Microperimetry and Low Luminance Visual Acuity as Endpoints in Clinical Trials for Geographic Atrophy







Date	Author	Title
04 Sep 2025	Fumi Gomi	A Multicenter Group-sequential Dose Escalation Phase I Study to Evaluate Safety and Pharmacokinetics of Tivozanib Eye Drops in Healthy Men and Neovascular Age-related Macular Degeneration Patients
04 Sep 2025	Michael Jacob	The impact of fluid dynamics on visual acuity in exudative macular neovascularization type 1: a long-term real-life AMD study
04 Sep 2025	Alexandra Miere	Can changes on OCTA predict exudative activity on OCT in eyes with neovascular age related macular degeneration? The ACTOR Study
04 Sep 2025	Prof Andreas Stahl	SPECTRUM: Month 6 results from the first global real-world study of aflibercept 8 mg in patients with previously treated neovascular age-related macular degeneration
04 Sep 2025	Dr. Shiri Shulman	Real World Efficacy and Durability of intravitreal faricimab as an advanced treatment line for NVAMD and DME - 24 month results
04 Sep 2025	Napatsorn Krisanuruks	Real-World Treatment Outcomes of Polypoidal Choroidal Vasculopathy: A Four-Year Study in Northern Thailand







Date	Author	Title Title
04 Sep 2025	Francesco Protti	Evaluation of OCT Biomarkers of Disease Progression in Fellow Eyes of Patients with Unilateral Neovascular Age-Related Macular Degeneration: A 3-Year Longitudinal Study
04 Sep 2025	Dr. Hemal Mehta	Resolution of retinal fluid after switching to faricimab in treatment-resistant neovascular age-related macular degeneration: sub-group analysis of the FURGGHORN clinical trial.
04 Sep 2025	Dr. Mahmoud Elbalawi	Long-Term Safety, Efficacy, and Operational Impact of Intravitreal Faricimab in Treating Neovascular Age- Related Macular Degeneration: A Real-World Evidence Study.
04 Sep 2025	Dr. Chu Hsuan Huang	Genome Wide Association Study in Neovascular Age-Related Macular Degeneration and The Correlation with Treatment Response to Anti-Vascular Endothelial Growth Factor
04 Sep 2025	Dr. Chrysa Agapitou	Anatomical and visual outcomes in patients with neovascular age-related macular degeneration treated with faricimab: Short-term results of a real-world study
04 Sep 2025	Dr. De-Kuang Hwang	Early Anatomical and Functional Outcomes of Faricimab vs. Aflibercept in Treatment-Naïve Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A Head-to-Head Comparative Study in Taiwan







Date	Author	Title Title
04 Sep 2025	Prof. Dr. Frank Holz	Assessing a 36-week refill-exchange regimen for the Port Delivery System with ranibizumab in patients with up to 2 years diagnosis of neovascular age-related macular degeneration: phase 3b Sightspire trial
04 Sep 2025	Dr. med. Christiana Dinah	LUGANO and LUCIA: Trial Design of Pivotal Phase 3 Studies of EYP-1901 vs Aflibercept in Neovascular Age- related Macular Degeneration
04 Sep 2025	Dr. Francesca Amoroso	SD-OCT and OCTA: distinct or additional information on neovascular activity? The COCTAEYL Study.
04 Sep 2025	Dr. Saad Younis	Evaluation of Prolonged Treatment Intervals and Injection Frequency for Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration: 26-Month Follow-Up Results
04 Sep 2025	Jordan Graff	The Phase 1/2 Burgundy Study of Zifibancimig Administered via Intravitreal Injection and the Port Delivery Platform in Patients With Neovascular Age-Related Macular Degeneration: Rationale and Study Design
04 Sep 2025	Ioannis Koumpoulis	Real-World Efficacy of Faricimab in Neovascular Age-Related Macular Degeneration: Insights from a Single-Center Study








Date	Author	Title
04 Sep 2025	Prof. Arshad M. Khanani	Real-World Efficacy and Safety of the Port-Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration: 2.5 Year Results of the SUMMIT Study
04 Sep 2025	Dr. Benjamin Scrivens	A real-world study to assess efficacy of switching to intravitreal Faricimab from intravitreal Aflibercept or Ranibizumab in patients with treatment resistant neovascular age-related macular degeneration: 2 year outcomes
04 Sep 2025	Dr. med. Adnan Kilani	Switch to Brolucizumab or Faricimab in Poor-Responsive Neovascular Age-related Macular Degeneration: A Comparison Study on Short-term and Long-term Responses
04 Sep 2025	Dr. Benjamin Scrivens	A real-world study to assess the efficacy of switching patients with resistant choroidal neovascularisation secondary to neovascular age-related macular degeneration to intravitreal faricimab: when to consider switching?
04 Sep 2025	Dr. Polina Biletska	One Shot, No Loading: Short-Term Results of the First 8mg Aflibercept Intravitreal Injection in the Upgrade of Neovascular Age-Related Macular Degeneration Treatment
04 Sep 2025	Prof. Gemmy Cheung	PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-related Macular Degeneration: 52-week Results








Date	Author	Title Title
05 Sep 2025	Mr Antoine POSNIC	Extension of the intra-vitreal injection interval after switching to faricimab in patients with exudative AMD: the multicenter FAR WEST study
05 Sep 2025	Clare Bailey	SPECTRUM: Early clinical outcomes in the first global real-world study of aflibercept 8 mg in patients with treatment-naive neovascular age-related macular degeneration
05 Sep 2025	Dr. Gabriella De Salvo	Effectiveness and Safety of Faricimab in nAMD Eyes Beyond Year 1: Results From the UK FARWIDE-nAMD Study
05 Sep 2025	Timothy Lai	Faricimab for Polypoidal Choroidal Vasculopathy: 1-Year Results From the Phase 3b/4 SALWEEN Trial
05 Sep 2025	David Almeida	Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: 3.5 Year Results of the TRUCKEE Study
05 Sep 2025	Dr. Usama Abdul Hussain	Real-World Twelve-Month Outcomes and Extension Data of Faricimab in Treatment-Resistant nAMD and DMO: A Multi-Centre Study








Date	Author	Title
05 Sep 2025	Prof. Robyn Guymer	Real-World Clinical and Anatomical OutcomesWith Faricimab in Patients WithnAMD From aGlobal, ProspectiveObservationalStudy: The VOYAGER Study
05 Sep 2025	Dr. Veeral Sheth	Four-Year Outcomes of Faricimab in nAMD: Safety and Efficacy Results From the AVONELLE-X Long-Term <u>Extension Trial</u>
06 Sep 2025	Prof. Sobha Sivaprasad	DAVIO 2 Phase 2 Clinical Trial Results: Vision Outcomes with EYP-1901 (Vorolanib Intravitreal Insert) Versus Aflibercept in Previously-Treated Neovascular Age-Related Macular Degeneration
06 Sep 2025	Dr. med. Christiana Dinah	DAVIO 2 Phase 2 Clinical Trial Results: Treatment Burden in Neovascular Age-related Macular Degeneration Treated with EYP-1901 (Vorolanib Intravitreal Insert) Versus Aflibercept
06 Sep 2025	Amy Siriphanh	Intraocular hypertension following Aflibercept 8 mg intravitreal injections, IOPA8 study
06 Sep 2025	Michael Singer	Pigment epithelial detachment outcomes with aflibercept 8 mg versus aflibercept 2 mg in the PULSAR trial: A 96-week post hoc analysis








Date	Author	Title
06 Sep 2025	Prof. Camiel J.F. Boon	The clinical spectrum of polypoidal choroidal vasculopathy in Caucasians: a retrospective multicenter cohort study
06 Sep 2025	Marco Battista	The PITCHFORK SIGN: a comparative structural OCT study in patients affected by inflammatoryand non- inflammatory choroidal neovascularization
06 Sep 2025	Dante Pieramici	Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for Neovascular Age-Related Macular Degeneration: Results of Bilateral Dosing from a Fellow Eye Study
06 Sep 2025	Eric Souied	One Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD
06 Sep 2025	Prof. Dr. Laurent Kodjikian	Pigment Epithelial Detachment Thickness Fluctuations in thePhase 3Archway Trial of thePDS in Neovascular Age-Related Macular Degeneration
06 Sep 2025	Prof. Arshad M. Khanani	First-Time Long-Term Efficacy and Safety Outcomes of PDS Patients Enrolled in the Ladder Phase 2 Trial of PDS for nAMD Followed for up to ~7 Years







Date	Author	Title Title
06 Sep 2025	Jordan Graff	Five-Year Efficacy and Safety Outcomes in Patients With Neovascular Age-Related Macular Degeneration Enrolled in the Archway Study and Treated With the PDS
06 Sep 2025	Dr. med. Isabel Buñola-Hadfield	Assessing vision related quality-of-life outcomes in neovascular age-related macular degeneration from the FASBAT study
06 Sep 2025	Prof. Sobha Sivaprasad	Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update
06 Sep 2025	Charles Wykoff	Ixoberogene soroparvovec intravitreal gene therapy for neovascular age-related macular degeneration (nAMD): Results from OPTIC and LUNA trials
06 Sep 2025	Lejla Vajzovic	Ixoberogene soroparvovec (Ixo-vec) intravitreal (IVT) gene therapy investigated for neovascular agerelated macular degeneration (nAMD): 4-Year safety and efficacy results from the Phase 1 OPTIC trial
06 Sep 2025	Prof. Dr. Ursula Schmidt-Erfurth	A 12-month multi-center study to compare standard-of-care with AI-based OCT guidance in the management of neovascular age-related macular degeneration (nAMD)





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (1/9)

Date	Author	Title
04 Sep 2025	Prof. Dr. Adrian Koh	Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With DME From a Global, Prospective Observational Study: The VOYAGER Study
04 Sep 2025	Dr. Xiaoli Chen	Influence of Glycosylated Hemoglobin on Faricimab Outcomes in the Treatment of Diabetic Macular Oedema: A Two-Year Study
04 Sep 2025	Prof. Corinne Dot	Long-term scar enlargment after conventional laser photocoagulation in TelCaps, the LyoMac 3 study
04 Sep 2025	Benedicte Dupas	Perifoveal retinal thickening (islets) after anti VEGF therapy in diabetic macular oedema : relationship with delayed ICG staining and oedema recurrence; the TelCaps/PVAC study group
04 Sep 2025	Usha Chakravarthy	A time in range analysis of the ILUVIEN Registry Safety Study
04 Sep 2025	Pınar Güran Beğar	Quantitative Analysis of Retinal and Choroidal Microvascular Changes in Diabetic Eyes with and without Retinopathy: A Two-Year Longitudinal Study





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (2/9)

Date	Author	Title Title
04 Sep 2025	Mr Raphael Lechtenboehmer	Smartphone-Based Retinal Imaging for Telemedical Diabetic Retinopathy Screening in Nigeria: Validation of Training by an Online E-Learning Course and Comparison with Results from India
04 Sep 2025	Mr Moiz Lakhani	The Association of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Treatment Burden: A Population-Based Epidemiological Study
04 Sep 2025	Dr. Maria Christine Dy	A Validation Study of a Novel Diabetic Retinopathy Awareness and Practice Assessment Filipino Questionnaire
04 Sep 2025	Mr Michael Grinton	The effect of Iluvien (Fluocinolone Acetonide) intravitreal implant in patients with Diabetic Macular Oedema with prior no or suboptimal response to Ozurdex (Dexamethasone) Implant: 24 month results.
04 Sep 2025	Hua Yan	Efficacy of Vitrectomy combined with Intravitreal Conbercept for treatment of Vitreous Hemorrhage from Proliferative Diabetic Retinopathy based on prospective cohort study
04 Sep 2025	Dr. Patricio Schlottmann	Restoret for the Treatment of Diabetic Macular Edema: Results from the AMARONE Phase 1b/2a Clinical Trial





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (3/9)

Date	Author	Title
04 Sep 2025	Dr. Varun Chaudhary	SPECTRUM: Early clinical outcomes in the first global real-world study of aflibercept 8 mg in patients with previously treated diabetic macular edema
04 Sep 2025	Noa Gilead	Incidence of Visual Loss in Patients with Diabetic Macular Ischemia A 1- year Prospective Study
04 Sep 2025	Prof. Ian Pearce	Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study
04 Sep 2025	Prof. Xufang Sun	A Randomized Controlled Trial of Anti-Vascular Endothelial Growth Factor Combined with Dexamethasone Implant in the Treatment of Macular Edema
04 Sep 2025	Stela Vujosevic	CRIMSON, a Phase IIb Randomized Controlled Trial of BI 764524 in Patients With Non-Proliferative Diabetic Retinopathy: Rationale, Study Design, and Protocol
04 Sep 2025	Margaret Chang	Macular Fluid Volumetric Outcomes Following a Single Axitinib Intravitreal Hydrogel (OTX-TKI) from the HELIOS Clinical Trial for Diabetic Retinopathy





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (4/9)

Date	Author	Title
04 Sep 2025	Dr. João Alves Ambrósio	Fluocinolone Acetonide for Persistent Diabetic Macular Edema with Suboptimal Response to Anti-VEGF Therapy: an OCT Biomarker-Based Study
04 Sep 2025	Patricia Udaondo Mirete	Week 96 outcomes in aflibercept 8 mg- and 2 mg-treated patients by prior DME treatment status: a subgroup analysis of the Phase 2/3 PHOTON trial
04 Sep 2025	Mr Christopher Brand	Risk of cataract or raised intraocular pressure in patients treated with dexamethasone intravitreal implants: Results from a retrospective UK database study.
04 Sep 2025	Dr. Vanessa Hilarry Tjen	One-year clinical efficacy and durability of intravitreal Faricimab versus Aflibercept(2mg) in treatment naïve eyes with diabetic macular oedema: A real-world, observational study
04 Sep 2025	Prof. Sarah Touhami	Faster Resolution of Subretinal Fluid in DME with DEX-I vs. Ranibizumab: A post-hoc analysis of a randomized trial
04 Sep 2025	Dr. Justis Ehlers	Quantitative Ultra-Widefield Fluorescein Angiography for the Assessment of Novel Biomarkers of Vascular Stability With Faricimab From the YOSEMITE/RHINE Clinical Trials





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (5/9)

Date	Author	Title
04 Sep 2025	David Almeida	VERONA End-of-Study Results: Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) Versus Aflibercept for the Treatment of Diabetic Macular Edema
04 Sep 2025	Sobha Sivaprasad	Aflibercept 8 mg in diabetic macular edema: 156-Week results from the PHOTON extension study
04 Sep 2025	Stephen Huddleston	Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
04 Sep 2025	Dr Christine Kiire	Effectiveness and Safety of Faricimab in Eyes With DME Beyond Year 1: Results From the UK FARWIDE- DME Study
04 Sep 2025	Margaret Chang	Patient perspectives on simulated study designs for an oral therapy for DME
04 Sep 2025	Madalena Goncalves	Predictive OCT Biomarkers and Fluid Dynamics in Diabetic Macular Edema Treated with Fluocinolone Acetonide Implant: 24-Month Real-World Functional and Anatomical Results





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (6/9)

Date	Author	Title
04 Sep 2025	Prof. Arshad M. Khanani	Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with <u>Diabetic Macular Edema</u>
04 Sep 2025	Jordan Graff	Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: Two-Year Results of the TAHOE Study
04 Sep 2025	Dr. Ana Avendaño- Flores	Efficacy and Safety of Intravitreal 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®) in Diabetic Macular Edema: A Bi-Center Retrospective Analysis Study
04 Sep 2025	Dr. Naresh Babu	INTRA SILICONE OIL METHOTREXATE INJECTION IN THE RESOLUTION OF SUB SILICONE OIL HEMORRHAGE IN DIABETIC TRACTIONAL DETACHMENT- A PROSPECTIVE RANDOMISED STUDY
04 Sep 2025	Patricia Udaondo Mirete	Faster Resolution of Central Intraretinal Cystoid Spaces in DME with DEX-I vs. Ranibizumab: A post-hoc analysis of a randomized trial
04 Sep 2025	Zelal Beşaltı	Is nepafenac 0.3% effective in central diabetic macular edema with good vision: SD-OCT Study





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (7/9)

Date	Author	Title Title
04 Sep 2025	Flavia Chiosi	The Impact of Hypertension on Choroidal Vascular Parameters in Type II Diabetes: A Correlative Study of Retrobulbar Hemodynamics and OCT Angiography
04 Sep 2025	Murat Arici	COMPARISON OF THE RESULTS OF DIFFERENT PATTERN LASER COAGULATION SYSTEMS APPLIED TO PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY IN TERMS OF COMFORT, DURATION AND INFLAMMATION
04 Sep 2025	Patrizio Bernadinelli	Comparative Analysis of Optos and Clarus Devices in Neovascularization and Diabetic Retinopathy Grading in the EviRed Study
04 Sep 2025	Dr. Gamze Ucan Gunduz	Nonpharmacological Aspects of Intravitreal Dexamethasone Implant Injections: A Retrospective Study of 3,430 Injections and Complications
04 Sep 2025	Miss Nicole Duarte	Progression of capillary hyperperfusion stage in advanced stages of NPDR: One-year analysis of RICHARD study
04 Sep 2025	Kun Liu	Association Between Long-term Serum Uric Acid Variability and Diabetic Retinopathy: A Prospective Study in Patients with Type 1 and Type 2 Diabetes





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (8/9)

Date	Author	Title
04 Sep 2025	Miss Débora Reste- Ferreira	Retinal neurodegeneration in eyes with mild to severe nonproliferative diabetic retinopathy: One year analysis of CHART study
04 Sep 2025	Annika Konttinen	A real life study: Visual outcomes in patients with type 2 diabetes (T2D) and diabetic macular edema (DME)
04 Sep 2025	Ioannis Koumpoulis	Real-World Efficacy of Faricimab in Diabetic Macular Edema: Insights from a Single-Center Study
04 Sep 2025	Theo Empeslidis	Presentation of rationalk and trial design of VX-01 DR201 a AOC3 inhibiotr for the treatment of NPDR
04 Sep 2025	Mr Panos Gartaganis	Evaluation of Prolonged Treatment Intervals and Injection Frequency for Intravitreal Faricimab in Diabetic Macular Oedema: 26-Month Follow-Up Results
04 Sep 2025	David Wright	Selecting measures of visual function to classify diabetic retinopathy status: a cross-sectional study





Notable Presentations And Late-breaking Sessions Diabetic Retinopathy & Diabetic Macular Edema (DR/DME) (9/9)

Date	Author	Title Title
05 Sep 2025	Prof. Dr. José Cunha-Vaz	One-year progression of the capillary hyperperfusion stage of severe nonproliferative diabetic retinopathy: The CHART study
05 Sep 2025	Dr. Marko Popovic	Large Retinal Capillary Aneurysm: A Delphi Consensus Study and Updated Nomenclature for a Signature Optical Coherence Tomography Lesion
07 Sep 2025	Patricia Udaondo Mirete	Bridging evidence and practice: challenges in translating DME trial results to real life



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (1/12)



Date	Author	Title Title
04 Sep 2025	Yelyzaveta Galytska	Clinical case of successful removal of foreign body from the anterior chamber angle in a patient after penetrating injury as a result of explosive trauma.
04 Sep 2025	Dr. Shulei Man	Retinal Layer and Vasculature Changes in Alzheimer's Disease: A Mendelian Randomization Study
04 Sep 2025	Fuxiang Zhang	A Simple Home-Based Ring Test Promotes Early Diagnosis of Retinal Detachment, Retinal Vacular Diseases and Common Optic Nerve DiseasesA Validation Study For Zhang Ring Test Used To Promote Early Detection.
04 Sep 2025	Dr. Claudio Xompero	Pilot Study Evaluation of ASSORT (AI-based Stratification of Symptoms in Ophthalmology for Rapid Triage): An AI-based Triage Tool for Ophthalmic Emergencies
04 Sep 2025	Prof. Dr. Marcel Menke	Early-Onset Ocular Pathologies: A Teleophthalmology-Based Screening Study in Individuals Aged 18-39 Years
04 Sep 2025	Dr. Ahmed Hassane	Clinically relevant factors associated with slow resolution of pseudophakic cystoid macular oedema – a multicentred retrospective study



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (2/12)



Date	Author	Title Title
04 Sep 2025	Dr. Rohan Kapoor	Predictive Biomarker on Optical Coherence Tomography for closure in Traumatic macular hole: A comparative study of Surgical vs. Observational intervention
04 Sep 2025	Ashish Sharma	Aflibercept 2mg Biosimilar (Tyalia) – Real-World Experience from IRAN (ATRIA Study)
04 Sep 2025	Dr. Adiel Barak	Supra SEG Microinjector Reduces Injection Forces for Safe Suprachoroidal Drug Delivery: A Rabbit Model Study
04 Sep 2025	Tomohiro Iida	Faricimab for Angioid Streaks in Japan: Week 12 Results From NIHONBASHI
04 Sep 2025	Carlos Moreira Neto	A Pilot Study of Intraoperative Melphalan to Prevent Recurrent PVR: The IOMPVR Study
04 Sep 2025	Ashish Sharma	Ranibizumab Biosimilar (Oceva) – Real-World Experience from India (RORE Study)



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (3/12)



Date	Author	Title
04 Sep 2025	Christian Wolfram	General quality of life for IVT-patients – Results from the German Register Study for the Treatment of Retinal Diseases (TRIGS)
04 Sep 2025	Alessio Martucci	Multicenter randomized double-blind trial evaluating the effect of poloxamer 407 and polyquaternium 133 eyedrops on conjunctival bacterial growth in patients undergoing anti-VEGF injection.
04 Sep 2025	Victor Kazaikin	Methods and results of measuring the height of the buckle using ultrasound B-scanning after applying a circular scleral buckle in the treatment of rhegmatogenous retinal detachment.
04 Sep 2025	Dr. DEEKSHA KATOCH	Role of 18% Sulphur hexafluoride (SF6) versus air tamponade in early postoperative vitreous cavity rebleed following vitrectomy for non-resolving vitreous haemorrhage in retinal vascular disease-A Prospective randomized study
04 Sep 2025	John Kitchens	Time Efficiency of Endo-Laser Pan-Retinal Photocoagulation Procedure with Multi-Spot Laser Probe: A Prospective, Comparative, Observational Time and Motion Study
04 Sep 2025	John Kitchens	Impact of the Next Generation of Vitreoretinal-cataract System on Vitreoretinal Surgery Efficiency: A Prospective, Comparative, Observational Time and Motion Study



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (4/12)



Date	Author	Title
04 Sep 2025	Dr. Naresh Babu	LONG TERM ANATOMICAL AND FUNCTIONAL OUTCOME OF REPEAT VITRECTOMY WITH PLATELET RICH PLASMA FOR REFRACTORY AND RE-OPENED FULL THICKNESS MACULAR HOLE: A PROSPECTIVE STUDY
04 Sep 2025	Dr. Gorsel Sali	Results of pars plana vitrectomy in patients with no light perception after ocular trauma and primary repair
04 Sep 2025	Dr. Prapti Chheda	Failed Pneumatic retinopexy: Outcomes and Associations. Pneumatic Retinopexy Indian Clinical Experience (PRICE) study group, Report 2.
04 Sep 2025	Hesna Cansu Aksoy	Long-Term Anatomical, Functional, and Vascular Outcomes in Macula-Off Rhegmatogenous Retinal Detachment Patients Undergoing Pars Plana Vitrectomy: An OCTA Study
04 Sep 2025	Nihat Sayin	The Results in Our Cases Undergoing Pneumatic Retinopexy
04 Sep 2025	Mr Asterios Diafas	Retinal Displacement Following Rhegmatogenous Retinal Detachment Repair: Scleral Buckling vs Pars Plana Vitrectomy (The BEVERLEY Study)



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (5/12)



Date	Author	Title
04 Sep 2025	Ana Lisa Carauni	Comparison of Vitrectomy Alone vs. Combined Vitrectomy with Scleral Buckling in Rhegmatogenous Retinal Detachment Surgery: A Follow-up Study
04 Sep 2025	Dr. Prakash Surendranath	Analysis of long-term anatomical and functional outcome in surgically managed cases of optic pit maculopathy: A retrospective study
04 Sep 2025	Dr. Sylvain el- Khoury	The Effect of Macular Thickness on Visual Acuity after Vitrectomy and ILM peeling: Results from the SCRV Macular Surgery Study.
04 Sep 2025	OGUZHAN KARABULUT	Surgical Management of Retinal Detachment Following Acute Retinal Necrosis (ARN): A Retrospective Study of 21 Cases
04 Sep 2025	PD Dr. med. Efstathios Vounotrypidis	Functional and OCT-based morphological results 1 year after vitrectomy for macula-off rhegmatogenous retinal detachment.
04 Sep 2025	Pedro Tañá Sanz	Comparative Study of Epiretinal Membrane Surgery Using Microincisional Vitrectomy With and Without Intravitreal Dexamethasone Implant



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (6/12)



Date	Author	Title
04 Sep 2025	Dr. Mootez Mourali	Clinical and Therapeutic Characteristics of Pediatric Rhegmatogenous Retinal Detachment: A Retrospective Study of 13 Cases
04 Sep 2025	Dr. Andrei Drimbea	Macular Hole 2024 study of the French Retina and Vitreous Surgical Society
04 Sep 2025	Dr. Aarush Deora	Pneumatic Retinopexy: Analysis of Risk Factors and Complications for Visual and Anatomical Results
04 Sep 2025	Dr. med. Caroline Bormann	Autologous platelet concentrate during vitrectomy for vitreomacular traction, epiretinal membrane foveoschisis and lamellar macular hole: functional and anatomic results
04 Sep 2025	MOUTEI HASSAN	Factors Influencing Visual Recovery After Silicone Oil Removal: A Study of 80 Eyes with Complicated Retinal Detachment
04 Sep 2025	John Kitchens	Console Set-Up and Tear-Down Time Efficiency for Vitreoretinal Surgery with Next Generation System: A Prospective, Comparative, Observational Time and Motion Study



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (7/12)



Date	Author	Title
04 Sep 2025	Prof. Dr. Rainer Guthoff	Long-term results after pars plana vitrectomy with gas endotamponade for optic pit maculopathy
04 Sep 2025	Prof. Jin-Ho Joo	Evaluation of Retinal Function Recovery After Epiretinal Membrane Peeling Surgery: A Prospective Study Using Full-Field Electroretinography
04 Sep 2025	Dr. Zung Mai	16 year - real world outcomes of Endophthalmitis rate and visual outcome after intravitreal injections versus cataract surgery: a retrospective single centred study.
04 Sep 2025	Dr. Ines SOFFER	Surgical treatment versus medical treatment as first-Line therapy in Endophthalmitis: A Retrospective Study from 2014 to 2024 in Brest
04 Sep 2025	Dr. med. Jörg- Christian Kirr	Comparative Teleophthalmology-Based Screening Study of Eye Morbidities in Switzerland and Germany
04 Sep 2025	Keith Lane	Opening Remarks: Shaping the Future of Retinal Trials



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (8/12)



Date	Author	Title
05 Sep 2025	ASHISH MARKAN	27-Gauge MIVS-Assisted Scleral Fixation of Intraocular Lens: An AS-OCT Guided Study
05 Sep 2025	Dr. Jeffrey Stolwijk	Phase 1/2a Trial of Suprachoroidal AXT107 (Gersizangitide) Delivered via Bella-vue a Novel Suprachoroidal Microneedle Device: Safety, Tolerability, and Usability Results
05 Sep 2025	Dr. Farah Nur Ilyana Mohd Ibrahim	Gender and Ethnic Diversity in Randomized Clinical Trials in Age Related Macular Degeneration and <u>Diabetic Macular Oedema.</u>
05 Sep 2025	Mr Moiz Lakhani	Ocular Adverse Events Associated with Faricimab: A Population-Based Pharmacovigilance Study
05 Sep 2025	Dr. Maximilian Pfau	Microperimetry in Clinical Trials: Best Practices for Reliable and Reproducible Data
05 Sep 2025	Prof. Paulo Stanga	Vitreous floaters and opacities YAG laser treatment: The first results of a two-year prospective controlled clinical trial.



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (9/12)



Date	Author	Title
05 Sep 2025	Dr. Abraham Olvera-Barrios	Incidence of sight-threatening diabetic retinopathy in pregnancy: A population-based study in a diverse cohort
05 Sep 2025	Dr. Ariel Y Ong	Microbiological sampling has limited value in managing acute postoperative bacterial endophthalmitis: a multicentre cohort study
05 Sep 2025	Dr. Sophie Bonnin	Improved Low Contrast Visual Acuity and Reduction in Retinal Ganglion Cell Loss with Privosegtor in Acute Optic Neuritis: Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial
05 Sep 2025	Dr. Luisa Frizziero	Correlation of Perfusion Deficits in the Macular and Peripapillary Areas versus Retinal Mid-periphery in Diabetic Retinopathy: a Wide-field OCT Angiography Study
05 Sep 2025	Dr. Sebastiano Del Fabbro	Risk analysis of retinal hemangioblastomas using ultra-widefield imaging in Von Hippel-Lindau syndrome: the ULTRA VHL study
05 Sep 2025	Dr Yuzhu Gao	Adaptive Optics Scanning Laser Ophthalmoscopy and Swept-Source Optical Coherence Tomography Reveal Photoreceptor and Outer Retinal Alterations and Their Association with Neuroimaging Features in Alzheimer's Disease: A Pilot Study



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (10/12)



Date	Author	Title
06 Sep 2025	Paolo Lanzetta	Phase 1 Study Results of OTX-TKI
06 Sep 2025	Prof. Sobha Sivaprasad	SOL-1 and SOL-R: Pivotal Phase 3 Trials Evaluating OTX-TKI for Wet AMD
06 Sep 2025	Prof. Diana Do	Clinical Findings from the LIGHTSITE III and IIIB Extension Trials
06 Sep 2025	Basil Williams	Is endophthalmitis vitrectomy study (EVS) still valid today
06 Sep 2025	Dr. med. Christiana Dinah	Emotionally Intelligent Research: Designing Trials That Care
06 Sep 2025	Dr. Ariel Y Ong	AI in ophthalmology - how to interpret if the study is valid?



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (11/12)



Date	Author	Title
06 Sep 2025	Prof. Dr. Matias Iglicki	"Technological Influence on Retina Fellows Learning Curves: A prospective Study of Digital vs. Analogical Microscopes ".The BRAVE Study"
06 Sep 2025	Prof. Matthew Simunovic	1-step vs. 2-step subretinal injection trial (1,2-SIT) – a randomized controlled trial to compare two methods of sub-retinal injection.
06 Sep 2025	Dr. Rita Teixeira- Martins	Subretinal Hemorrhage: Clinical Profile and Visual Results of Intravitreal Alteplase Injection
06 Sep 2025	Dr. Mariapaola Giordano	Evaluation of ChatGPT-40 in Identifying Exudative Recurrence in Wet Age-Related Macular Degeneration: A Comparative Study with Expert Ophthalmologists
06 Sep 2025	Nathalie Skovgaard Eriksen	Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-Analysis, and Forecasting Study
06 Sep 2025	Bart LeRoy	Challenges in Genetic Testing: does a negative result always rule out an IRD?



Notable Presentations And Late-breaking Sessions Surgical Retina, Trauma, Imaging/AI, Devices, Drug Delivery, Biosimilars, Epidemiology & QoL (12/12)



Date	Author	Title
06 Sep 2025	SALVADOR PASTOR-IDOATE	Analysis of Visual and Inflammatory Outcomes in Patients with Silicone Oil Tamponade Following Complex Retinal Detachment: A Multicenter Study
06 Sep 2025	Dr. Muthukrishnan Vallinayagam	Evaluation of Anatomical and Functional Outcomes of Relaxing Retinectomy in Recurrent Retinal Detachment - A Retrospective Observational Study
06 Sep 2025	Dr. Jan Tode	Photothermal Laser Therapy for the Treatment of Intermediate AMD. An Insight into the MacuTherm Trial
06 Sep 2025	PABLO REDRUELLO- GUERRERO	Classification of therapies in submacular hemorrhagesecondary to age-related macular degeneration: results of a network meta-analysis
06 Sep 2025	Dr. med. Johannes Schrittwieser	Personalized shared screening and identification of age-related macular degeneration using telemedicine matching community-based sites with clinical supervision (PYRENEES): I-Screen study







Date	Author	Title Title
04 Sep 2025	Liping Yang	Efficacy and safety of ZVS101e (AAV2/8-hCYP4V2) in patients with Bietti Crystalline Corneoretinal Dystrophy: a phase 1/2 trial
04 Sep 2025	Dr. Wenhui Zhou	Safety and Efficacy of ZM-02 Optogenetic Gene Therapy clinical Study for Advanced Retinitis Pigmentosa
04 Sep 2025	Prof. Dr. Yasuhiro Ikeda	A phase I/IIa investigator-initiated clinical trial of neuroprotective gene therapy using DVC1-0401 in patients with retinitis pigmentosa
04 Sep 2025	Mechteld van Olden	Symmetric Retinal Sensitivity Decline in USH2A-related Retinitis Pigmentosa Supports Feasibility of a Paired-Eye Design in Future Clinical Trials
04 Sep 2025	Yara Khamis	Prevalence of Refractive Errors among individuals with Inherited Retinal Dystrophies and individuals with Normal Retina: A comparative study in the Arab Region
04 Sep 2025	Marco Nassisi	Early ocular phenotype and progression of Cobalamin C deficiency: retrospective longitudinal study of an Italian cohort.







Date	Author	Title
04 Sep 2025	Dr. Aydan Koçar	Retinal and Choroidal Microvasculature in Retinitis Pigmentosa: A Comparative Study with Healthy Controls
04 Sep 2025	Miss Marta Moro- Muniz	STUDY OF THE PERIPHERAL INFLAMMATION IN PATIENTS WITH HEREDITARY RETINAL DYSTROPHIES
04 Sep 2025	Marta Danikiewicz- Zagała	The results of idebenone treatment in siblings with early onset of autosomal recessive Leber Hereditary Optic Neuropathy (arLHON)
04 Sep 2025	Shaima Awadh Hashem	PDE6A-Associated Retinitis Pigmentosa: A Longitudinal Study of Clinical Characteristics, Genetics, and Disease Progression
04 Sep 2025	David Almeida	Safety and Efficacy of Novel Modifier Gene Therapy OCU410ST for Treatment of Stargardt Disease: Phase 1/2 Study Update
04 Sep 2025	Michel Michaelides	Interim Analysis from a Phase 3 Study of Oral Tinlarebant in Childhood Onset Stargardt Disease (DRAGON)







Date	Author	Title Title
04 Sep 2025	Dr. Kenneth Fan	A novel modifier gene therapy for retinitis pigmentosa: a phase 1/2 multicentre study of subretinal OCU400
04 Sep 2025	Paul Yang	Subretinal laru-zova Gene Therapy for XLRP: 36-Month Results of the Randomized, Controlled, Multicenter Phase 2 SKYLINE Trial
04 Sep 2025	FRCS, FRCOphth Rajiv Anand	Subretinal gene therapy laru-zova for X-linked retinitis pigmentosa (XLRP): Phase 2 DAWN Trial, preliminary month 9 results
04 Sep 2025	Francesca Simonelli	LUCE-1: a first-in-human, phase 1/2 multicenter, dose escalation, safety and efficacy study of subretinal administration of dual hybrid AAVB-081 gene therapy in subjects with Usher Syndrome type 1B Retinitis Pigmentosa
04 Sep 2025	Fred Chen	A Phase 1B Multiple Ascending Dose Study of VP-001; a peptide conjugate of oligonucleotide designed to treat PRPF31-related Retinitis Pigmentosa
04 Sep 2025	Prof. Dr. Isabelle Audo	PRODYGY: A First-in-Human Trial of Rod-Derived Cone Viability Factor (RdCVF) Gene Therapy in Subjects with Rod-Cone Dystrophy





Notable Presentations And Late-breaking Sessions Inherited Retinal Diseases & Gene/Cell Therapies (4/4)

Date	Author	Title Title
04 Sep 2025	Prof. Dominik Fischer	Long-term safety and effectiveness of voretigene neparvovec: 5-Year interim results of the PERCEIVE real- world study
04 Sep 2025	José Guerra	Outcomes of Cataract Surgery in Patients with Retinitis Pigmentosa: A Local Restropective Study
05 Sep 2025	Jordi Monés	REMAIN: 152-Week Extended Analysis From the RESTORE Study of MCO-010 Optogenetic Therapy for Retinitis Pigmentosa



Notable Presentations And Late-breaking Sessions Uveitis, Inflammation & Infection; Ocular Tumors (1/3)



Date	Author	Title Title
04 Sep 2025	Athanasios Pappas	Vitreoretinal Lymphoma through the Decades: Results from a Single-Center Experience
04 Sep 2025	Dr. Marta García Díaz	Results of external beam radiotherapy in choroidal infiltration secondary to follicular lymphoma: a case report and literature review
04 Sep 2025	Marta Vila Franca	Choroidal Vascularity Index in Patients with Choroidal Nevus: A Quantitative OCT Imaging Study
04 Sep 2025	Dr. Mahima Jhingan	Efficacy and tolerability of adalimumab in patients with birdshot retinochoroiditis: results from a large tertiary centre.
04 Sep 2025	Dr. Paria Bolourinejad	Acute Retinal Necrosis in Isfahan; A Ten-Year Retrospective Study
04 Sep 2025	Prof. Dr. Chun Ju Lin	Risk of Uveitis in Dengue Fever Patients: A Population-Based Cohort Study in Taiwan



Notable Presentations And Late-breaking Sessions Uveitis, Inflammation & Infection; Ocular Tumors (2/3)



Date	Author	Title
04 Sep 2025	Prof. Dr. Chun Ju Lin	Risk of uveitis among E-Cigarette Users: a multi-institutional TriNetX study
04 Sep 2025	Mr Hamza Abdou	Dexamethasone versus Fluocinolone acetonide intravitreal implants in patients with uveitic macular edema: a retrospective comparative study
04 Sep 2025	Dr. Shristi Shristi	Intravenous Ceftriaxone As An Alternative Treatment For Syphilitic Uveitis: A Case Study In North Indian Population
04 Sep 2025	Dr. Yong-Un Shin	Epidemiologic study of pediatric uveitis and its ophthalmic complications using the Korean National Health <u>Insurance Claim Database</u>
04 Sep 2025	Mr Muhammad Raza Cheema	Clinical characteristics and visual outcomes in Bartonella Henselae (cat scratch disease) in New Zealand: A 23 - year Analysis study
05 Sep 2025	Dr. Carmen Antía Rodríguez- Fernández	ADALIMUMAB IN NON-INFECTIOUS UVEITIS: REAL-WORLD STUDY ON LONG-TERM DISEASE CONTROL





Notable Presentations And Late-breaking Sessions Uveitis, Inflammation & Infection; Ocular Tumors (3/3)

Date	Author	Title
06 Sep 2025	Dr. Anna Giulia Di Dario	Somatic genomic prognostication of uveal melanoma: long-term study on metastatic risk and survival





Notable Presentations And Late-breaking Sessions Retinal Vascular Occlusions (RVO/CRVO/BRVO/CRAO) (1/2)

Date	Author	Title
04 Sep 2025	Dr. Abdi Malik Musa	Impact of Systolic and Mean Arterial Pressure on Intravitreal Injection Frequency in CRVO and BRVO patients: A prospective cohort study
04 Sep 2025	Alexandra Miere	Change in retinal perfusion with aflibercept for central retinal vein occlusion: the two-year prospective observational HERMES study
04 Sep 2025	Dr. Yong Wei	Anti-VEGF instead of laser photocoagulation during Vitrectomy for Branch Retinal Vein Occlusion combined with Vitreous Hemorrhage: a randomized clinical trial
04 Sep 2025	Michael Singer	First Time Clinical Trial Results Phase 2a Open-label, Dose Ascending, Safety, Tolerability and Proof of Concept Study to Evaluate ANXV (Human Recombinant Annexin A5) in the treatment-naive Subjects with Recently Diagnosed Retinal Vein Occlusion.
04 Sep 2025	Prof. Dr. Anne Hege Aamodt	TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY(TenCRAOS): Main results
05 Sep 2025	Mr Richard Gale	Aflibercept 8 mg in treatment-naïve macular edema secondary to retinal vein occlusion: Primary endpoint results from the QUASAR study





Notable Presentations And Late-breaking Sessions Retinal Vascular Occlusions (RVO/CRVO/BRVO/CRAO) (2/2)

Date	Author	Title Title
05 Sep 2025	Dr. Varun Chaudhary	Results from the QUASAR study: Comparable vision gains with aflibercept 8 mg and 2 mg in treatment- naïve macular edema secondary to retinal vein occlusion
06 Sep 2025	Dr. med. Christiana Dinah	Association of Early Macular Leakage Resolution With Extended Dosing Intervals in Patients With RVO: A Post Hoc Analysis of the BALATON/COMINO Trials







Date	Author	Title Title
04 Sep 2025	Jost Jonas	Prevalence and Associations of Reticular Pseudodrusen in Age-Related Macular Degeneration. The Beijing <u>Eye Study</u>
04 Sep 2025	Jost Jonas	Prevalence and Associations of Intraretinal Hyperreflective Bodies in Age-Related Macular Degeneration. The Beijing Eye Study
04 Sep 2025	Wei Kiong Ngo	Prevalence of Retinal Pigment Epithelium and Outer Retinal Atrophy in Eyes from a Population-based Study Cohort of Octogenarians Living in Singapore
04 Sep 2025	Bjørn André Helland-Hansen	Dynamic Pupillary Responses in Age-Related Macular Degeneration: A Controlled Clinical Study Using High- Frequency Video-Oculography
04 Sep 2025	Dr. CORINNE GONZALEZ	AMD: Structural, Morphology and Evolution study of Drusenoid deposits with OCT and Morphology- Structural software.
04 Sep 2025	Prof. Robyn Guymer	Intermediate AMD risk markers and clinical trial endpoints







Date	Author	Title Title
04 Sep 2025	Ignacio Flores- Moreno	Tractional Myopic Maculopathy, Progression Study.
04 Sep 2025	Telma Machado	LONG-TERM PROGRESSION OF MYOPIC MACULOPATHY IN EYES WITH CNV: A MULTICENTER LONGITUDINAL STUDY
04 Sep 2025	Dr. Nour Kammoun	microvasculature in High Myopia without pathologic changes: An OCT and OCT-Angiography Study
04 Sep 2025	Akos Vadnay	Anterior segment measurements in cases of myopia progression control DIMS lens 36 month results
04 Sep 2025	Akos Vadnay	Pachymetry results in myopia progression control DIMS lens 36 month results





Notable Presentations And Late-breaking Sessions Pachychoroid Spectrum & Central Serous Chorioretinopathy

Date	Author	Title	
04 Sep 2025	Dr. giulia ribezzi	Optimizing Resolution in Pachychoroid Neovasculopathy: A Swept-Source OCTA Study	
05 Sep 2025	Dr. Parul Yadav	EVALUATING THE SAFETY AND EFFICACY OF TOPICAL DIFLUPREDNATE IN PATIENTS WITH CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND COMPARISION WITH ORAL EPLERENONE – AN OPEN LABEL RANDOMISED CONTROL TRIAL	
05 Sep 2025	Dr. med. Songhomitra Panda-Jonas	Prevalence and Associations of Central Serous Chorioretinopathy. The Beijing Eye Study.	
05 Sep 2025	Dr. Srishti Ramamurthy	Randomized Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy with persistent fluid without choroidal neovascular membrane	





Key Industry Sponsored Sessions Information



EURETINA 2025 Key Industry Sponsored Sessions Information (1/4)



Date	Sponsor	Title Title
04 Nov 2025	Bayer	Evolving Practice in Retinal Care: The Journey from Lab to Patient
04 Nov 2025	Roche	Real-World Decisions with Real-World Data
04 Nov 2025	Ora	Rethinking Retina: Building Smarter Clinical Trials for a Global Clinical Execution
05 Nov 2025	Alcon	Achieving Superior Efficiency in Vitreoretinal Surgery
05 Nov 2025	icare	Advancing Retinal Imaging: Current Trends and Future Directions
05 Nov 2025	Lumibird Medical	Changing And Rethinking Vitreous And Retinal Treatments With Lasers
05 Nov 2025	AbbVie	Spotlight on Inflammation: Evolving the Management of DME and RVO



EURETINA 2025 Key Industry Sponsored Sessions Information (2/4)



Date	Sponsor	Title Title	
05 Nov 2025	Roche	THROUGH OUR PATIENTS' EYES: Patient voices in the era of continuous drug delivery for retinal disease	
05 Nov 2025	optos	Enhancing Patient Care Through Innovation: The Power of Ultra-widefield Imaging and Navigated Peripheral OCT	
05 Nov 2025	Bayer	From Data to Decisions: What Do We See in the Real World?	
05 Nov 2025	Astellas	Geographic Atrophy Patient Management: What Do You See? What Would You Do?	
05 Nov 2025	Heidelberg Engineering	<u>Innovations in Imaging – Transforming Patient Care</u>	
05 Nov 2025	Roche	The nAMD Challenge: Looking Beyond VEGF-A Inhibition	
05 Nov 2025	Amgen	Decoding Biosimilars and Biosimilar Development	



EURETINA 2025 Key Industry Sponsored Sessions Information (3/4)



Date	Sponsor	Title	
05 Nov 2025	Espansione group	Light Modulation™ LLLT (PBM): A New Frontier in Retinal Care & Beyond	
05 Nov 2025	Micro Clear	SKY Launch, Odyssey From Retina To Cornea	
06 Nov 2025	Ocular	Advancing Retinal Disease Treatment: Exploring OTX-TKI's Potential to Extend Treatment Durability	
06 Nov 2025	Roche	Advocating for Innovative Therapies: Everything You Need to Know	
06 Nov 2025	Zeiss	Illuminating Diabetic Retinopathy: Using Diagnostic Imaging and Advanced Surgical Visualization to <u>Enhance Patient Care</u>	
06 Nov 2025	LumiThera	Photobiomodulation Therapy for Dry AMD: Insights from 4.5 Years of Follow-up from the LIGHTSITE IIIB Trial	
06 Nov 2025	4DMT	Intravitreal Gene Therapy: A New Era of Durable Treatment for Retinal Vascular Diseases with 4D-150	



EURETINA 2025 Key Industry Sponsored Sessions Information (4/4)



Date	Sponsor	Title Title
06 Nov 2025	Nidek	Diagnostic Pursuits Using Advanced Insights into Morphologic Changes in Chorioretinal Disease
06 Nov 2025	Roche	The DME Challenge: Looking Beyond VEGF-A Inhibition
06 Nov 2025	Bayer	The Time is Now: Lead the Way to Shape the Future
06 Nov 2025	AbbVie	Updates in AI-driven OCT Biomarker Analysis to Optimise Treatment for DME and RVO





Noteworthy AI / ML presentations at EURETINA 2025







Themes from key AI / ML presentations at EURETINA 2025 (1/3)

- EURETINA 2025 AI and machine learning are set to transform ophthalmology by establishing reproducible biomarkers, scalable screening models, and novel clinical trial endpoints, driving precision care across AMD, DME, GA, and beyond
- Check out the key AI / ML themes at EURETINA 2025 below:
- AI in AMD & Neovascularization:
 - AI is expected to enable OCT-based AMD classification, biomarker quantification, and structural endpoints, with validation projected in TENAYA/LUCERNE comparing Faricimab versus Aflibercept
- AI in Diabetic Retinopathy & DME:
 - AI is anticipated to expand DR/DME screening, with EyeArt projected for large-scale validation and AIDME enhancing accuracy in treatment response prediction
- AI in Geographic Atrophy:
 - Deep learning is set to provide reproducible GA lesion quantification, supporting standardized trial endpoints and consistent real-world monitoring





Themes from key AI / ML presentations at EURETINA 2025 (2/3)

AI in Retinal Imaging & Biomarkers:

 Multimodal AI is expected to integrate OCT, OCTA, and UWF imaging, identifying emerging biomarkers such as peripapillary choroidal vascularity index and retinal pigment scoring

AI in Surgical Retina & Vitrectomy:

 Machine learning is positioned to predict outcomes post-vitrectomy for ERM and transform vitreoretinal surgery planning through advanced algorithms

AI in Clinical Trials & Endpoints:

 AI is projected to define novel digital endpoints in AMD and X-linked retinoschisis, supporting regulatory acceptance across global clinical programs

AI in Teleophthalmology & Cost-Effectiveness:

 Smartphone-based AI screening is expected to scale in underserved regions, with costeffectiveness studies shaping adoption in low-resource healthcare systems





Themes from key AI / ML presentations at EURETINA 2025 (3/3)

AI Beyond Ophthalmology:

 AI-based OCT approaches are anticipated to predict intraocular cytokines and coronary artery disease, expanding diagnostic applications beyond ophthalmology

AI in Personalized Therapy Selection:

AI is expected to match imaging biomarkers with drug response, enabling tailored use
of Faricimab, Aflibercept, or gene therapy in complex retinal disease profiles.

AI in Real-World Evidence Generation:

 AI is anticipated to streamline analysis of large retinal registries, providing insights into long-term treatment durability, adherence patterns, and population-level outcomes

AI in Regulatory and Ethical Frameworks:

 AI adoption is set to prompt regulatory alignment and ethical oversight, ensuring transparency, reproducibility, and safe integration into clinical decision-making pathways

AI in Education and Clinical Training:

 AI-driven simulators are projected to transform ophthalmology training, supporting surgical planning, diagnostic accuracy, and standardized skill development for future retina specialists





Noteworthy AI / ML presentations at EURETINA 2025



Notable presentations at EURETINA 2025 AI/ ML (1/9)



Date	Author	Title Title
04 Sep 2025	Dr. med. Isabel Bachmeier	Deep learning OCT segmentation of subretinal hyperreflective material subtypes in neovascular AMD: Dynamics and associations with visual outcomes
04 Sep 2025	Dr. Nicolò Bartolomeo	Early outcome analysis of intravitreal Aflibercept 8mg injections in naïve patients with neovascular age-related macular degeneration using artificial intelligence.
04 Sep 2025	Anna Heinke	Artificial Intelligence for Cross-Platform Fine-Grained Classification of Age-Related Macular Degeneration Using Enface OCTA Images
04 Sep 2025	Prof. Ruth Hogg	Predicting Age-related macular degeneration severity using visual function measures using both traditional statistical methods and interpretable machine learning.
04 Sep 2025	Dana Taghaddos	Artificial Intelligence for Screening, Diagnosis, and Treatment of Central Serous Chorioretinopathy: A Systematic Review
04 Sep 2025	Dr. Vishaal Bhambhwani	Screening for diabetic retinopathy with artificial intelligence in a primary care setting: a cost-effectiveness analysis



Notable presentations at EURETINA 2025 AI/ ML (2/9)



Date	Author	Title Title
04 Sep 2025	Dr. Mohaimen Al- Zubaidy	A Scoping Review of the Use of Artificial Intelligence Models in Automated OCT Analysis and Prediction of Treatment Outcomes in Diabetic Macular Oedema
04 Sep 2025	Heiko Stino	Influence of localized features in diabetic macular edema on point-wise retinal sensitivity using deep learning
04 Sep 2025	JUAN DONATE- LÓPEZ	Artificial Intelligence-Driven Adjusted Scoring-Based Classification System for Diabetic Macular Edema (AIDME)
04 Sep 2025	Dr. Jasmine Ge	Implementation of artificial intelligence (AI) assisted diabetic retinopathy (DR) screening in suburban area of Yangon, Myanmar
04 Sep 2025	Dr. med. Sila Bekiroglu	Evaluation of Geographic Atrophy (GA) Lesion Measurements and Growth Rates using Semi-automated and Artificial Intelligence (AI) software
04 Sep 2025	Dr. Vlad Diaconita	Accurate Measurement of Geographic Atrophy Area from Cross-Sectional OCT Images by Deep Learning Algorithm



Notable presentations at EURETINA 2025 AI/ ML (3/9)



Date	Author	Title Title
04 Sep 2025	Prof. Jose Maria Ruiz Moreno	Exploratory study on a novel Automatic Quantification Software by Artificial Intelligence for Geographic Atrophy Associated to Age-Related Macular Degeneration
04 Sep 2025	Prof. Dr. Erdinc Aydin	Novel Approach: Automated Coronary Artery Disease Detection Based on Deep Learning via Optical Coherence <u>Tomography Images</u>
04 Sep 2025	Dr. Yu Jin Kim	Repeatability and reproducibility of automated hard exudates analysis with an AI program in fundus photographs
04 Sep 2025	Hidenori Takahashi	Prediction of Intraocular Cytokine Concentrations from Optical Coherence Tomography Images Using Machine <u>Learning</u>
04 Sep 2025	Dr. Saloni Une	Comparison of swept source-OCT based foveal (clivus) angle measurements in normal adults and children using artificial intelligence- based algorithm versus manual measurement in ImageJ software program
04 Sep 2025	Dr. Nicola Valsecchi	Peripapillary choroidal vascularity index as a novel biomarker for differentiating papilledema from pseudopapilledema: a deep learning-based approach



Notable presentations at EURETINA 2025 AI/ ML (4/9)



Date	Author	Title Title
04 Sep 2025	Dr. Mahmoud Yassine SALAH SALAH	Multimodal Deep Learning and Artificial Intelligence for Enhanced Diabetic Retinopathy Diagnosis
04 Sep 2025	Dr. Claudia Fossataro	Regulatory Issues and Challenges to Artificial Intelligence Adoption in Ophthalmology: What Lies Ahead?
04 Sep 2025	Luis Nakayama	Multimodal Deep Learning for Retinal Images in Low-Resource Settings: Vector Embedding Alignment for Diabetic Retinopathy Screening
04 Sep 2025	Dr. Wei Yan Ng	Novel Artificial Intelligence (AI) Choroidal Segmentation of Optical Coherence Tomography (OCT) Scans in Eyes with Pathologic Myopia
04 Sep 2025	PD Dr. med. Christos Skevas	Deep Learning for Automated Detection of Retinal Detachment: Evaluating Duration and Macular Status
04 Sep 2025	Dr. Lasse Jørgensen Cehofski	Incomplete Response to Anti-VEGF Therapy in Diabetic Macular Edema – Integration of Proteomics and Artificial Intelligence



Notable presentations at EURETINA 2025 AI/ ML (5/9)



Date	Author	Title Title
04 Sep 2025	Dr. Nassim Bouteldja	Towards Scalable Preventive Eye Care: A Multimodal AI Solution for Identifying Patients in Need of Referral
04 Sep 2025	Dr. Wei Yan Ng	Novel Artificial Intelligence (AI) Choroidal Segmentation of Optical Coherence Tomography (OCT) Scans in Eyes with Pathologic Myopia
04 Sep 2025	John Peter Campbell	Imaging and AI prediction of ROP
04 Sep 2025	Dr. Sumit Randhir Singh	Diagnostic accuracy of artificial intelligence (AI) algorithm integrated with a smartphone-based fundus camera in retina and glaucoma disorders.
04 Sep 2025	Dr. Lorenzo Ferro Desideri	Artificial Intelligence Analysis of OCT Biomarkers to Predict Visual Outcomes Following Vitrectomy for Epiretinal Membrane
04 Sep 2025	Dr. Shaswath Ganapathi	Mixed methods, consensus study to develop a Target Product Profile for artificial intelligence-enabled health technologies for use in the English diabetic eye screening programme.



Notable presentations at EURETINA 2025 AI/ ML (6/9)



Date	Author	Title Title
04 Sep 2025	Dr. Tien-En Tan	Artificial intelligence-quantified schisis volume as a structural endpoint for gene therapy clinical trials in X-linked retinoschisis
05 Sep 2025	Anna Heinke	Artificial Intelligence for Cross-Platform Fine-Grained Classification of Age-Related Macular Degeneration Using Enface OCTA Images
05 Sep 2025	Ms Mingyue Wang	Screening for pathology on colour fundal images using Artificial Intelligence
05 Sep 2025	Dr. Haras Mhmud	Deep learning-based quantification of intermediate age-related macular degeneration biomarkers for predicting geographic atrophy and neovascularization
05 Sep 2025	Dr. Omer Triviski	The Role of AI in Defining Clinical Trial Endpoints in A
05 Sep 2025	Dr. Sandy Wenting Zhou	Artificial Intelligence-Assisted Automated Grading of Diabetic Retinopathy using Ultrawide Field Swept Source Optical Coherence Tomography Angiography (UWF-SSOCTA).



Notable presentations at EURETINA 2025 AI/ ML (7/9)



Date	Author	Title Title
05 Sep 2025	Maria Ludovica Ruggeri	Development of a machine learning enabling OCT-based algorithm to assign regenerative therapy modality in patients with hereditary retinal disorders
05 Sep 2025	Paolo Lanzetta	Machine Learning-Based 3D Volumetric Analysis of Pigment Epithelial Detachment Reduction With Faricimab vs Aflibercept in TENAYA/LUCERNE
05 Sep 2025	Dr. Nicola Valsecchi	Peripapillary choroidal vascularity index as a novel biomarker for differentiating papilledema from pseudopapilledema: a deep learning-based approach
05 Sep 2025	Tina Felfeli	Assessing the EyeArt Artificial Intelligence-Based System for Diabetic Retinopathy Screening in the Toronto Tele- Retinal Screening Program
05 Sep 2025	Dr. Abraham Olvera-Barrios	Retinal pigment score to assess diabetic retinopathy (DR) detection across multiple artificial intelligence vendors in a large diverse cohort
05 Sep 2025	Dr. Hugo Le Boite	Deep Learning based evaluation of retinal non-perfusion on OCT-Angiography in diabetic retinopathy



Notable presentations at EURETINA 2025 AI/ ML (8/9)



Date	Author	Title Title
06 Sep 2025	Patricia Udaondo Mirete	Hands-On and Future of AI in vitreoretinal practice
06 Sep 2025	Sobha Sivaprasad	Why we should consider deploying AI now
06 Sep 2025	Dr. George Moussa	Beyond Deep Learning: Mathematical Innovations and Machine Learning in Vitreoretinal Surgery
06 Sep 2025	Giovanni Neri	Deep Learning Model for Automated Classification of Macular Neovascularization Subtypes in A
06 Sep 2025	Gregor Reiter	Artificial intelligence for identifying structure-function relationships in retinal diseases
07 Sep 2025	Dr. Ariel Y Ong	Artificial intelligence as a medical device for ophthalmic image analysis in Europe, Australia, and the United States: a systematic scoping review of regulated devices



Notable presentations at EURETINA 2025 AI/ ML (9/9)



Date	Author	Title Title
07 Sep 2025	Prof. Edoardo Midena	From bench to AI in DME
07 Sep 2025	Daniel Ting	A state of the art on artificial intelligence developments in diabetic retinopathy
07 Sep 2025	Siegfried Wagner	How does AI help understanding brain diseases?



Strategic Insights and Strategy Development is our focus

